Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
India | 232 | 2024 | 2334 | 9.700 |
Why?
|
Hypertension | 87 | 2024 | 8616 | 5.530 |
Why?
|
Cardiovascular Diseases | 115 | 2024 | 15662 | 5.000 |
Why?
|
Urban Population | 32 | 2024 | 2046 | 3.420 |
Why?
|
Diabetes Mellitus | 42 | 2024 | 5889 | 3.060 |
Why?
|
Developing Countries | 37 | 2024 | 2910 | 2.990 |
Why?
|
Rural Population | 34 | 2024 | 2325 | 2.450 |
Why?
|
Blood Pressure | 52 | 2024 | 8543 | 2.320 |
Why?
|
Acute Coronary Syndrome | 37 | 2018 | 2194 | 2.260 |
Why?
|
Yoga | 7 | 2022 | 280 | 2.160 |
Why?
|
Antihypertensive Agents | 28 | 2024 | 2029 | 2.030 |
Why?
|
Sodium, Dietary | 9 | 2021 | 426 | 1.780 |
Why?
|
Ticlopidine | 21 | 2017 | 730 | 1.770 |
Why?
|
Platelet Aggregation Inhibitors | 33 | 2021 | 2763 | 1.720 |
Why?
|
Metabolic Diseases | 8 | 2020 | 684 | 1.660 |
Why?
|
Diabetes Mellitus, Type 2 | 38 | 2024 | 12252 | 1.560 |
Why?
|
Cardiology | 11 | 2024 | 1702 | 1.500 |
Why?
|
Blood Pressure Determination | 9 | 2020 | 646 | 1.470 |
Why?
|
Diet | 32 | 2023 | 8089 | 1.460 |
Why?
|
Telemedicine | 10 | 2024 | 3109 | 1.440 |
Why?
|
Chronic Disease | 19 | 2024 | 9384 | 1.390 |
Why?
|
Quality Improvement | 17 | 2024 | 3857 | 1.340 |
Why?
|
Particulate Matter | 7 | 2024 | 2617 | 1.330 |
Why?
|
Health Promotion | 12 | 2021 | 2210 | 1.310 |
Why?
|
Risk Factors | 132 | 2024 | 74944 | 1.290 |
Why?
|
Prevalence | 55 | 2024 | 15869 | 1.230 |
Why?
|
Apolipoproteins B | 5 | 2024 | 386 | 1.220 |
Why?
|
Humans | 429 | 2024 | 768166 | 1.210 |
Why?
|
Myocardial Infarction | 35 | 2021 | 11519 | 1.180 |
Why?
|
Delivery of Health Care, Integrated | 8 | 2019 | 951 | 1.180 |
Why?
|
Health Priorities | 4 | 2018 | 380 | 1.160 |
Why?
|
Risk Reduction Behavior | 14 | 2024 | 1119 | 1.130 |
Why?
|
Cost of Illness | 10 | 2024 | 1951 | 1.110 |
Why?
|
Decision Support Systems, Clinical | 13 | 2024 | 1178 | 1.100 |
Why?
|
Life Style | 18 | 2024 | 3932 | 1.090 |
Why?
|
Primary Health Care | 17 | 2023 | 4746 | 1.070 |
Why?
|
Cross-Sectional Studies | 80 | 2024 | 26379 | 1.070 |
Why?
|
Pakistan | 16 | 2024 | 299 | 1.060 |
Why?
|
Air Pollution | 7 | 2024 | 2374 | 1.050 |
Why?
|
Environmental Exposure | 8 | 2024 | 4543 | 1.040 |
Why?
|
Sodium Chloride, Dietary | 10 | 2023 | 301 | 1.040 |
Why?
|
Meditation | 4 | 2022 | 257 | 1.010 |
Why?
|
Dyslipidemias | 12 | 2023 | 873 | 1.010 |
Why?
|
Income | 13 | 2023 | 1878 | 0.970 |
Why?
|
Air Pollutants | 6 | 2024 | 2916 | 0.940 |
Why?
|
Diet, Vegetarian | 5 | 2024 | 181 | 0.940 |
Why?
|
Male | 237 | 2024 | 364719 | 0.940 |
Why?
|
Female | 255 | 2024 | 397192 | 0.930 |
Why?
|
Diabetes, Gestational | 6 | 2024 | 1263 | 0.930 |
Why?
|
Middle Aged | 179 | 2024 | 223492 | 0.930 |
Why?
|
Health Knowledge, Attitudes, Practice | 11 | 2024 | 4055 | 0.920 |
Why?
|
Biomedical Research | 9 | 2019 | 3463 | 0.920 |
Why?
|
Adult | 174 | 2024 | 223646 | 0.910 |
Why?
|
Cardiovascular System | 2 | 2023 | 841 | 0.900 |
Why?
|
Primary Prevention | 10 | 2021 | 1188 | 0.890 |
Why?
|
Socioeconomic Factors | 32 | 2024 | 7852 | 0.880 |
Why?
|
Risk Assessment | 33 | 2024 | 24315 | 0.850 |
Why?
|
Preventive Health Services | 2 | 2019 | 570 | 0.830 |
Why?
|
Bibliometrics | 3 | 2015 | 354 | 0.820 |
Why?
|
Obesity | 33 | 2023 | 13090 | 0.820 |
Why?
|
Child, Orphaned | 1 | 2023 | 55 | 0.810 |
Why?
|
Prenatal Care | 5 | 2024 | 1162 | 0.800 |
Why?
|
Cities | 10 | 2024 | 543 | 0.790 |
Why?
|
Blood Glucose | 22 | 2024 | 6430 | 0.780 |
Why?
|
Health Surveys | 10 | 2023 | 4057 | 0.780 |
Why?
|
Adipokines | 1 | 2024 | 309 | 0.770 |
Why?
|
Morbidity | 7 | 2024 | 1755 | 0.760 |
Why?
|
Takayasu Arteritis | 1 | 2023 | 106 | 0.750 |
Why?
|
Asia | 15 | 2020 | 629 | 0.750 |
Why?
|
Nurse's Role | 2 | 2022 | 188 | 0.730 |
Why?
|
Heart Failure | 15 | 2024 | 11879 | 0.730 |
Why?
|
Communicable Disease Control | 4 | 2023 | 857 | 0.730 |
Why?
|
Practice Guidelines as Topic | 15 | 2023 | 7454 | 0.710 |
Why?
|
Atherosclerosis | 6 | 2024 | 3433 | 0.710 |
Why?
|
Urbanization | 8 | 2021 | 100 | 0.710 |
Why?
|
Social Class | 7 | 2017 | 2008 | 0.690 |
Why?
|
Secondary Prevention | 9 | 2024 | 1474 | 0.690 |
Why?
|
Capacity Building | 3 | 2019 | 265 | 0.690 |
Why?
|
Angina, Unstable | 9 | 2018 | 893 | 0.690 |
Why?
|
DDT | 1 | 2019 | 32 | 0.680 |
Why?
|
Cholesterol, HDL | 8 | 2024 | 1820 | 0.670 |
Why?
|
Epidemiologic Studies | 3 | 2014 | 677 | 0.670 |
Why?
|
Remote Consultation | 1 | 2022 | 242 | 0.660 |
Why?
|
Dichlorodiphenyl Dichloroethylene | 1 | 2019 | 85 | 0.660 |
Why?
|
Coronary Disease | 8 | 2021 | 5919 | 0.650 |
Why?
|
Obesity, Abdominal | 5 | 2024 | 375 | 0.650 |
Why?
|
Prediabetic State | 7 | 2024 | 548 | 0.640 |
Why?
|
Sodium Chloride | 2 | 2018 | 584 | 0.640 |
Why?
|
Food Industry | 3 | 2018 | 68 | 0.610 |
Why?
|
Waist Circumference | 8 | 2022 | 935 | 0.600 |
Why?
|
Multicenter Studies as Topic | 6 | 2024 | 1737 | 0.590 |
Why?
|
Coronary Artery Disease | 14 | 2023 | 6568 | 0.590 |
Why?
|
Mortality | 9 | 2024 | 2911 | 0.590 |
Why?
|
Body Mass Index | 28 | 2024 | 13053 | 0.580 |
Why?
|
Aged | 116 | 2024 | 171504 | 0.570 |
Why?
|
Vitamin D Deficiency | 5 | 2023 | 1388 | 0.560 |
Why?
|
Qualitative Research | 9 | 2021 | 3140 | 0.560 |
Why?
|
Aspirin | 15 | 2021 | 3135 | 0.560 |
Why?
|
Nutrition Policy | 2 | 2018 | 467 | 0.550 |
Why?
|
Communicable Diseases | 2 | 2023 | 874 | 0.550 |
Why?
|
Pesticides | 1 | 2019 | 298 | 0.540 |
Why?
|
Cholesterol, LDL | 10 | 2024 | 2403 | 0.540 |
Why?
|
Disease Management | 7 | 2019 | 2536 | 0.540 |
Why?
|
Pandemics | 10 | 2023 | 8748 | 0.530 |
Why?
|
Physicians, Primary Care | 3 | 2020 | 624 | 0.530 |
Why?
|
Lipids | 4 | 2021 | 3343 | 0.520 |
Why?
|
Feeding Behavior | 9 | 2023 | 3205 | 0.520 |
Why?
|
Diabetes Complications | 4 | 2021 | 1320 | 0.520 |
Why?
|
Drug Therapy, Combination | 20 | 2021 | 6316 | 0.520 |
Why?
|
School Health Services | 1 | 2019 | 388 | 0.510 |
Why?
|
Incidence | 27 | 2024 | 21538 | 0.500 |
Why?
|
Dental Caries | 1 | 2019 | 429 | 0.490 |
Why?
|
Amlodipine | 4 | 2022 | 84 | 0.490 |
Why?
|
Exercise | 14 | 2022 | 5955 | 0.480 |
Why?
|
Poverty | 7 | 2020 | 2720 | 0.480 |
Why?
|
Electrocardiography | 12 | 2023 | 6412 | 0.480 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2024 | 10399 | 0.480 |
Why?
|
Patient Care Team | 5 | 2019 | 2523 | 0.480 |
Why?
|
Nutrition Surveys | 5 | 2021 | 1738 | 0.470 |
Why?
|
Health Status | 9 | 2022 | 4091 | 0.460 |
Why?
|
Biomedical Technology | 2 | 2016 | 210 | 0.460 |
Why?
|
Thiophenes | 6 | 2014 | 570 | 0.460 |
Why?
|
Family | 3 | 2017 | 3209 | 0.450 |
Why?
|
Leadership | 4 | 2024 | 1397 | 0.450 |
Why?
|
Cost-Benefit Analysis | 15 | 2023 | 5536 | 0.450 |
Why?
|
Oral Health | 1 | 2019 | 493 | 0.450 |
Why?
|
Guideline Adherence | 6 | 2017 | 2235 | 0.450 |
Why?
|
Follow-Up Studies | 37 | 2024 | 39348 | 0.440 |
Why?
|
Human Development | 1 | 2014 | 122 | 0.440 |
Why?
|
Stroke | 25 | 2022 | 9755 | 0.440 |
Why?
|
Food Preferences | 2 | 2018 | 398 | 0.440 |
Why?
|
Periodicals as Topic | 3 | 2015 | 1465 | 0.440 |
Why?
|
Family Characteristics | 4 | 2017 | 1003 | 0.430 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2023 | 3251 | 0.430 |
Why?
|
Triglycerides | 9 | 2024 | 2464 | 0.430 |
Why?
|
Public Health Administration | 1 | 2016 | 242 | 0.430 |
Why?
|
Postpartum Period | 4 | 2024 | 1198 | 0.430 |
Why?
|
Anticholesteremic Agents | 2 | 2018 | 972 | 0.420 |
Why?
|
Young Adult | 49 | 2024 | 60066 | 0.420 |
Why?
|
Public-Private Sector Partnerships | 1 | 2014 | 123 | 0.420 |
Why?
|
Coronary Artery Bypass | 7 | 2017 | 2191 | 0.410 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2024 | 2298 | 0.410 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3115 | 0.410 |
Why?
|
Depressive Disorder | 2 | 2017 | 3721 | 0.410 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3238 | 0.410 |
Why?
|
Anthropometry | 10 | 2022 | 1346 | 0.400 |
Why?
|
Cohort Studies | 27 | 2024 | 41754 | 0.390 |
Why?
|
Chlorthalidone | 3 | 2022 | 21 | 0.390 |
Why?
|
Respiratory Tract Diseases | 1 | 2017 | 744 | 0.390 |
Why?
|
Genetic Predisposition to Disease | 11 | 2024 | 18065 | 0.390 |
Why?
|
Glucose Intolerance | 5 | 2024 | 579 | 0.380 |
Why?
|
Early Diagnosis | 2 | 2016 | 1194 | 0.380 |
Why?
|
Cardiovascular Agents | 5 | 2021 | 849 | 0.370 |
Why?
|
Food Supply | 4 | 2023 | 544 | 0.370 |
Why?
|
Africa | 9 | 2024 | 725 | 0.360 |
Why?
|
Forecasting | 2 | 2017 | 2945 | 0.360 |
Why?
|
Delivery of Health Care | 8 | 2024 | 5367 | 0.360 |
Why?
|
Coronary Artery Bypass, Off-Pump | 4 | 2016 | 65 | 0.360 |
Why?
|
Heart Diseases | 5 | 2021 | 2819 | 0.350 |
Why?
|
Decision Support Techniques | 2 | 2018 | 2008 | 0.350 |
Why?
|
Quality of Life | 11 | 2022 | 13490 | 0.350 |
Why?
|
Overweight | 8 | 2023 | 2448 | 0.340 |
Why?
|
Aryldialkylphosphatase | 1 | 2010 | 64 | 0.340 |
Why?
|
Research | 3 | 2021 | 1979 | 0.340 |
Why?
|
Hyperuricemia | 1 | 2013 | 222 | 0.340 |
Why?
|
Tobacco Use Disorder | 2 | 2015 | 708 | 0.340 |
Why?
|
Sex Distribution | 6 | 2020 | 2278 | 0.340 |
Why?
|
Adolescent | 37 | 2024 | 89169 | 0.330 |
Why?
|
Time Factors | 31 | 2024 | 40218 | 0.330 |
Why?
|
Commerce | 2 | 2023 | 612 | 0.320 |
Why?
|
Blood Pressure Monitors | 2 | 2021 | 33 | 0.320 |
Why?
|
Internationality | 3 | 2023 | 1008 | 0.320 |
Why?
|
Urban Health | 3 | 2020 | 535 | 0.320 |
Why?
|
Docosahexaenoic Acids | 3 | 2021 | 914 | 0.320 |
Why?
|
Mass Screening | 9 | 2021 | 5458 | 0.310 |
Why?
|
Medical History Taking | 1 | 2012 | 779 | 0.310 |
Why?
|
Hemorrhage | 10 | 2018 | 3467 | 0.310 |
Why?
|
Adiposity | 6 | 2024 | 1895 | 0.310 |
Why?
|
Health Behavior | 7 | 2021 | 2650 | 0.300 |
Why?
|
Population Surveillance | 3 | 2014 | 2596 | 0.300 |
Why?
|
Age Factors | 13 | 2024 | 18412 | 0.300 |
Why?
|
Homocysteine | 1 | 2011 | 637 | 0.300 |
Why?
|
Piperazines | 6 | 2014 | 2554 | 0.290 |
Why?
|
Pregnant Women | 2 | 2023 | 576 | 0.290 |
Why?
|
Smoking | 8 | 2020 | 9092 | 0.290 |
Why?
|
Child Development | 4 | 2021 | 2330 | 0.290 |
Why?
|
Health Resources | 3 | 2020 | 950 | 0.290 |
Why?
|
Diet Surveys | 4 | 2019 | 1160 | 0.290 |
Why?
|
Lipoproteins, LDL | 2 | 2010 | 644 | 0.290 |
Why?
|
Dietary Supplements | 5 | 2021 | 3445 | 0.290 |
Why?
|
Public Policy | 2 | 2014 | 552 | 0.290 |
Why?
|
Poverty Areas | 3 | 2017 | 268 | 0.280 |
Why?
|
Guidelines as Topic | 5 | 2019 | 1397 | 0.280 |
Why?
|
Vitamin D | 5 | 2023 | 3311 | 0.280 |
Why?
|
Treatment Outcome | 45 | 2024 | 65371 | 0.280 |
Why?
|
Prognosis | 19 | 2024 | 30010 | 0.280 |
Why?
|
Rural Health | 3 | 2014 | 302 | 0.280 |
Why?
|
Publishing | 1 | 2014 | 837 | 0.270 |
Why?
|
Argentina | 4 | 2016 | 249 | 0.270 |
Why?
|
Tobacco Use Cessation | 2 | 2018 | 100 | 0.270 |
Why?
|
Self Care | 3 | 2018 | 799 | 0.270 |
Why?
|
Hydrochlorothiazide | 3 | 2017 | 95 | 0.270 |
Why?
|
Medication Therapy Management | 2 | 2020 | 131 | 0.270 |
Why?
|
Energy Intake | 6 | 2020 | 2146 | 0.270 |
Why?
|
Stress, Psychological | 4 | 2017 | 4530 | 0.270 |
Why?
|
Hospitalization | 9 | 2022 | 10840 | 0.260 |
Why?
|
Transients and Migrants | 4 | 2020 | 170 | 0.260 |
Why?
|
Developed Countries | 4 | 2014 | 451 | 0.260 |
Why?
|
Nutritional Status | 5 | 2017 | 1628 | 0.260 |
Why?
|
Evidence-Based Medicine | 5 | 2020 | 3706 | 0.260 |
Why?
|
Health Policy | 8 | 2020 | 2698 | 0.260 |
Why?
|
Health Personnel | 7 | 2022 | 3385 | 0.260 |
Why?
|
Education | 2 | 2019 | 533 | 0.260 |
Why?
|
Hypercholesterolemia | 2 | 2010 | 1145 | 0.260 |
Why?
|
Hyperglycemia | 2 | 2016 | 1388 | 0.250 |
Why?
|
Glucose Tolerance Test | 3 | 2024 | 1183 | 0.250 |
Why?
|
Prospective Studies | 28 | 2024 | 54926 | 0.250 |
Why?
|
Evidence-Based Practice | 4 | 2020 | 500 | 0.250 |
Why?
|
Health Services Accessibility | 8 | 2021 | 5520 | 0.250 |
Why?
|
Sex Factors | 11 | 2024 | 10632 | 0.250 |
Why?
|
Bangladesh | 4 | 2024 | 742 | 0.250 |
Why?
|
Educational Status | 6 | 2019 | 2515 | 0.250 |
Why?
|
Cause of Death | 7 | 2019 | 3721 | 0.240 |
Why?
|
Food Labeling | 2 | 2018 | 181 | 0.240 |
Why?
|
Community Health Services | 3 | 2019 | 659 | 0.240 |
Why?
|
Sri Lanka | 5 | 2024 | 93 | 0.240 |
Why?
|
Comorbidity | 9 | 2022 | 10590 | 0.240 |
Why?
|
Benzoates | 2 | 2018 | 213 | 0.240 |
Why?
|
Cardiology Service, Hospital | 2 | 2019 | 242 | 0.230 |
Why?
|
Logistic Models | 10 | 2019 | 13290 | 0.230 |
Why?
|
Apolipoprotein A-I | 2 | 2020 | 305 | 0.230 |
Why?
|
Registries | 12 | 2023 | 8375 | 0.230 |
Why?
|
Longitudinal Studies | 9 | 2024 | 14783 | 0.230 |
Why?
|
Polymorphism, Genetic | 2 | 2016 | 4249 | 0.230 |
Why?
|
Emergency Medical Services | 5 | 2023 | 1947 | 0.230 |
Why?
|
Life Expectancy | 4 | 2020 | 1248 | 0.230 |
Why?
|
Quality Indicators, Health Care | 4 | 2019 | 1805 | 0.220 |
Why?
|
Quality of Health Care | 5 | 2024 | 4310 | 0.220 |
Why?
|
Cultural Characteristics | 3 | 2020 | 250 | 0.220 |
Why?
|
Education, Medical, Continuing | 2 | 2019 | 829 | 0.220 |
Why?
|
Patients | 2 | 2021 | 908 | 0.220 |
Why?
|
Health Care Costs | 4 | 2019 | 3239 | 0.210 |
Why?
|
Mentors | 2 | 2019 | 671 | 0.210 |
Why?
|
Residence Characteristics | 5 | 2017 | 2118 | 0.210 |
Why?
|
Polymorphism, Single Nucleotide | 10 | 2021 | 16045 | 0.210 |
Why?
|
Glomerular Filtration Rate | 2 | 2024 | 2227 | 0.210 |
Why?
|
Stroke Volume | 5 | 2024 | 5622 | 0.210 |
Why?
|
Feasibility Studies | 7 | 2022 | 5315 | 0.210 |
Why?
|
Interviews as Topic | 5 | 2019 | 2741 | 0.210 |
Why?
|
Dairying | 1 | 2022 | 12 | 0.200 |
Why?
|
Occupational Health | 1 | 2009 | 812 | 0.200 |
Why?
|
Body Size | 2 | 2019 | 463 | 0.200 |
Why?
|
Maternal Nutritional Physiological Phenomena | 3 | 2020 | 395 | 0.200 |
Why?
|
Insulin Resistance | 5 | 2022 | 3986 | 0.200 |
Why?
|
Perception | 2 | 2021 | 1209 | 0.200 |
Why?
|
Medication Adherence | 5 | 2018 | 2187 | 0.200 |
Why?
|
Telecommunications | 2 | 2013 | 79 | 0.200 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3231 | 0.200 |
Why?
|
Malnutrition | 4 | 2020 | 632 | 0.200 |
Why?
|
Diet, Sodium-Restricted | 4 | 2020 | 291 | 0.200 |
Why?
|
Kaplan-Meier Estimate | 11 | 2016 | 6526 | 0.200 |
Why?
|
Drug Combinations | 9 | 2024 | 2089 | 0.190 |
Why?
|
Walking | 3 | 2018 | 1201 | 0.190 |
Why?
|
Environmental Health | 1 | 2024 | 298 | 0.190 |
Why?
|
Purinergic P2Y Receptor Antagonists | 5 | 2016 | 285 | 0.190 |
Why?
|
Patient Admission | 3 | 2020 | 1365 | 0.190 |
Why?
|
Fast Foods | 3 | 2021 | 220 | 0.190 |
Why?
|
Alcohol Drinking | 4 | 2021 | 4045 | 0.190 |
Why?
|
Emigration and Immigration | 5 | 2014 | 406 | 0.190 |
Why?
|
South Africa | 5 | 2024 | 1873 | 0.190 |
Why?
|
Prevotella intermedia | 1 | 2021 | 17 | 0.190 |
Why?
|
Aged, 80 and over | 18 | 2024 | 59629 | 0.190 |
Why?
|
Nitrogen Dioxide | 1 | 2024 | 534 | 0.190 |
Why?
|
Pregnancy | 15 | 2024 | 30256 | 0.190 |
Why?
|
Iodine | 1 | 2023 | 285 | 0.190 |
Why?
|
Chemokine CCL2 | 1 | 2024 | 605 | 0.190 |
Why?
|
Odds Ratio | 8 | 2019 | 9669 | 0.190 |
Why?
|
Environmental Monitoring | 2 | 2024 | 1469 | 0.190 |
Why?
|
Health Expenditures | 4 | 2020 | 2389 | 0.190 |
Why?
|
Imidazoline Receptors | 1 | 2020 | 13 | 0.180 |
Why?
|
Demography | 6 | 2014 | 1641 | 0.180 |
Why?
|
Case-Control Studies | 8 | 2024 | 22291 | 0.180 |
Why?
|
Teaching | 2 | 2019 | 1171 | 0.180 |
Why?
|
Bronchitis, Chronic | 1 | 2022 | 82 | 0.180 |
Why?
|
China | 4 | 2016 | 2395 | 0.180 |
Why?
|
Nurses | 2 | 2021 | 2501 | 0.180 |
Why?
|
Ozone | 1 | 2024 | 496 | 0.180 |
Why?
|
Public Health | 5 | 2022 | 2679 | 0.180 |
Why?
|
Benzimidazoles | 2 | 2018 | 864 | 0.180 |
Why?
|
Employment | 3 | 2017 | 1110 | 0.180 |
Why?
|
Leukoplakia, Oral | 1 | 2021 | 79 | 0.180 |
Why?
|
Arsenic | 1 | 2024 | 358 | 0.180 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2021 | 131 | 0.180 |
Why?
|
Population Dynamics | 3 | 2012 | 314 | 0.180 |
Why?
|
Platelet Activation | 2 | 2015 | 644 | 0.180 |
Why?
|
Porphyromonas gingivalis | 1 | 2021 | 165 | 0.180 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2022 | 3252 | 0.180 |
Why?
|
Mothers | 3 | 2022 | 2209 | 0.170 |
Why?
|
Peru | 3 | 2023 | 890 | 0.170 |
Why?
|
Double-Blind Method | 14 | 2021 | 12465 | 0.170 |
Why?
|
Quality Assurance, Health Care | 3 | 2016 | 2176 | 0.170 |
Why?
|
Birth Weight | 5 | 2021 | 2121 | 0.170 |
Why?
|
Cholesterol | 4 | 2023 | 2914 | 0.170 |
Why?
|
City Planning | 1 | 2019 | 14 | 0.170 |
Why?
|
Environmental Pollution | 1 | 2021 | 125 | 0.170 |
Why?
|
Fusobacterium nucleatum | 1 | 2021 | 176 | 0.170 |
Why?
|
Rheumatic Heart Disease | 1 | 2021 | 164 | 0.170 |
Why?
|
Patient Education as Topic | 4 | 2024 | 2337 | 0.170 |
Why?
|
Program Evaluation | 4 | 2019 | 2507 | 0.170 |
Why?
|
Prenatal Nutritional Physiological Phenomena | 1 | 2021 | 161 | 0.170 |
Why?
|
Lisinopril | 2 | 2017 | 60 | 0.170 |
Why?
|
Asia, Western | 3 | 2015 | 19 | 0.170 |
Why?
|
Investments | 1 | 2021 | 149 | 0.160 |
Why?
|
Depressive Disorder, Major | 1 | 2017 | 4818 | 0.160 |
Why?
|
Uruguay | 2 | 2016 | 104 | 0.160 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2021 | 241 | 0.160 |
Why?
|
Atenolol | 2 | 2017 | 99 | 0.160 |
Why?
|
Apolipoprotein B-100 | 1 | 2020 | 157 | 0.160 |
Why?
|
Health Facility Administrators | 1 | 2019 | 32 | 0.160 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2022 | 352 | 0.160 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2023 | 340 | 0.160 |
Why?
|
Fasting | 5 | 2022 | 1610 | 0.160 |
Why?
|
Electronic Health Records | 4 | 2024 | 4887 | 0.160 |
Why?
|
Models, Organizational | 4 | 2019 | 548 | 0.160 |
Why?
|
Alanine Transaminase | 1 | 2022 | 606 | 0.160 |
Why?
|
Health Status Disparities | 3 | 2017 | 1885 | 0.160 |
Why?
|
Workplace | 2 | 2019 | 873 | 0.160 |
Why?
|
Proportional Hazards Models | 9 | 2019 | 12543 | 0.160 |
Why?
|
Blood Specimen Collection | 3 | 2010 | 238 | 0.160 |
Why?
|
Retrospective Studies | 18 | 2024 | 81762 | 0.150 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2023 | 2909 | 0.150 |
Why?
|
Potassium | 2 | 2020 | 1315 | 0.150 |
Why?
|
Breast Feeding | 4 | 2022 | 1363 | 0.150 |
Why?
|
Chile | 2 | 2016 | 258 | 0.150 |
Why?
|
Decision Trees | 1 | 2020 | 508 | 0.150 |
Why?
|
Geographic Information Systems | 2 | 2017 | 283 | 0.150 |
Why?
|
Health Services | 2 | 2023 | 755 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 11 | 2020 | 10760 | 0.150 |
Why?
|
C-Reactive Protein | 3 | 2024 | 3858 | 0.150 |
Why?
|
Pharmacists | 1 | 2020 | 261 | 0.150 |
Why?
|
Bone Density | 3 | 2017 | 3573 | 0.150 |
Why?
|
Needs Assessment | 3 | 2019 | 1141 | 0.150 |
Why?
|
International Agencies | 2 | 2016 | 244 | 0.150 |
Why?
|
Thrombosis | 2 | 2011 | 2957 | 0.150 |
Why?
|
Child | 18 | 2024 | 80917 | 0.150 |
Why?
|
Mental Health | 1 | 2012 | 3275 | 0.150 |
Why?
|
Food, Preserved | 1 | 2017 | 13 | 0.150 |
Why?
|
Eligibility Determination | 1 | 2021 | 421 | 0.150 |
Why?
|
Body Weight | 5 | 2021 | 4627 | 0.150 |
Why?
|
Food-Processing Industry | 1 | 2017 | 14 | 0.150 |
Why?
|
Clinical Trials as Topic | 3 | 2017 | 8054 | 0.150 |
Why?
|
Cluster Analysis | 4 | 2019 | 2732 | 0.150 |
Why?
|
Angina Pectoris | 2 | 2019 | 957 | 0.140 |
Why?
|
Pelvic Bones | 2 | 2017 | 274 | 0.140 |
Why?
|
Environment | 2 | 2021 | 1121 | 0.140 |
Why?
|
Patient Compliance | 5 | 2020 | 2697 | 0.140 |
Why?
|
Health Status Indicators | 2 | 2019 | 969 | 0.140 |
Why?
|
Diabetic Nephropathies | 1 | 2024 | 973 | 0.140 |
Why?
|
South America | 4 | 2019 | 180 | 0.140 |
Why?
|
Hot Temperature | 1 | 2024 | 1441 | 0.140 |
Why?
|
Atrial Fibrillation | 3 | 2023 | 5176 | 0.140 |
Why?
|
Age Distribution | 4 | 2020 | 2873 | 0.140 |
Why?
|
Research Design | 9 | 2020 | 6211 | 0.140 |
Why?
|
Survival Rate | 9 | 2021 | 12840 | 0.140 |
Why?
|
Indians, North American | 1 | 2021 | 354 | 0.140 |
Why?
|
Asia, Southeastern | 2 | 2018 | 115 | 0.140 |
Why?
|
Simvastatin | 2 | 2017 | 346 | 0.140 |
Why?
|
Ventricular Function, Left | 3 | 2021 | 3941 | 0.140 |
Why?
|
Patient Discharge | 3 | 2022 | 3479 | 0.140 |
Why?
|
Depression | 2 | 2014 | 8230 | 0.140 |
Why?
|
Neoplasms | 7 | 2024 | 22371 | 0.140 |
Why?
|
Gastrointestinal Hormones | 1 | 2017 | 101 | 0.140 |
Why?
|
Mental Disorders | 2 | 2017 | 6874 | 0.140 |
Why?
|
Quantitative Trait, Heritable | 1 | 2020 | 540 | 0.140 |
Why?
|
Micronutrients | 2 | 2017 | 390 | 0.140 |
Why?
|
Seafood | 1 | 2020 | 395 | 0.130 |
Why?
|
Societies, Medical | 3 | 2020 | 3968 | 0.130 |
Why?
|
Models, Theoretical | 5 | 2024 | 3573 | 0.130 |
Why?
|
Meta-Analysis as Topic | 1 | 2021 | 1363 | 0.130 |
Why?
|
Cooperative Behavior | 2 | 2013 | 1514 | 0.130 |
Why?
|
Sodium | 2 | 2023 | 1597 | 0.130 |
Why?
|
Phosphates | 1 | 2020 | 765 | 0.130 |
Why?
|
Economic Development | 1 | 2017 | 72 | 0.130 |
Why?
|
World Health Organization | 4 | 2020 | 1329 | 0.130 |
Why?
|
DNA, Bacterial | 1 | 2021 | 1478 | 0.130 |
Why?
|
Aftercare | 1 | 2022 | 916 | 0.130 |
Why?
|
Fabaceae | 1 | 2016 | 103 | 0.130 |
Why?
|
Inservice Training | 1 | 2018 | 375 | 0.130 |
Why?
|
Public Sector | 1 | 2017 | 266 | 0.130 |
Why?
|
Proteinuria | 1 | 2019 | 611 | 0.130 |
Why?
|
Hypotension | 1 | 2022 | 888 | 0.130 |
Why?
|
Environment Design | 1 | 2017 | 174 | 0.130 |
Why?
|
Milk | 2 | 2022 | 438 | 0.130 |
Why?
|
Health Transition | 1 | 2015 | 35 | 0.130 |
Why?
|
Vegetables | 3 | 2023 | 1199 | 0.130 |
Why?
|
Patient Care Management | 1 | 2019 | 303 | 0.130 |
Why?
|
Hospital Administration | 1 | 2019 | 351 | 0.120 |
Why?
|
Severity of Illness Index | 6 | 2020 | 15948 | 0.120 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2023 | 997 | 0.120 |
Why?
|
Intra-Abdominal Fat | 2 | 2024 | 625 | 0.120 |
Why?
|
Physicians | 4 | 2021 | 4598 | 0.120 |
Why?
|
Lipid Metabolism | 2 | 2014 | 1904 | 0.120 |
Why?
|
Certification | 1 | 2018 | 420 | 0.120 |
Why?
|
Remote Sensing Technology | 1 | 2016 | 93 | 0.120 |
Why?
|
Attitude of Health Personnel | 2 | 2019 | 3929 | 0.120 |
Why?
|
United States | 12 | 2023 | 73039 | 0.120 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2021 | 2145 | 0.120 |
Why?
|
Brain Ischemia | 2 | 2020 | 3007 | 0.120 |
Why?
|
Diffusion of Innovation | 2 | 2017 | 724 | 0.120 |
Why?
|
Geography | 2 | 2014 | 652 | 0.120 |
Why?
|
Restaurants | 1 | 2017 | 234 | 0.120 |
Why?
|
Policy Making | 1 | 2018 | 546 | 0.120 |
Why?
|
Reference Standards | 1 | 2018 | 1014 | 0.120 |
Why?
|
Health Care Surveys | 3 | 2024 | 2434 | 0.110 |
Why?
|
Polypharmacy | 1 | 2017 | 307 | 0.110 |
Why?
|
Drug Substitution | 1 | 2017 | 291 | 0.110 |
Why?
|
National Health Programs | 2 | 2015 | 442 | 0.110 |
Why?
|
Fibroblast Growth Factors | 1 | 2020 | 873 | 0.110 |
Why?
|
Wounds and Injuries | 3 | 2024 | 2517 | 0.110 |
Why?
|
Lipoprotein(a) | 1 | 2018 | 489 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2024 | 3228 | 0.110 |
Why?
|
Insulin | 6 | 2022 | 6607 | 0.110 |
Why?
|
Marketing | 1 | 2016 | 224 | 0.110 |
Why?
|
Platelet Function Tests | 4 | 2016 | 275 | 0.110 |
Why?
|
Nutritional Sciences | 2 | 2022 | 148 | 0.110 |
Why?
|
Poisson Distribution | 1 | 2015 | 506 | 0.110 |
Why?
|
Latin America | 1 | 2015 | 416 | 0.110 |
Why?
|
Europe | 5 | 2024 | 3436 | 0.110 |
Why?
|
Motor Activity | 3 | 2014 | 2711 | 0.110 |
Why?
|
Inflammation | 4 | 2022 | 10873 | 0.110 |
Why?
|
Cytokines | 3 | 2024 | 7453 | 0.110 |
Why?
|
Social Change | 1 | 2014 | 152 | 0.110 |
Why?
|
Quality-Adjusted Life Years | 3 | 2023 | 1741 | 0.110 |
Why?
|
Parathyroid Hormone | 1 | 2020 | 1804 | 0.110 |
Why?
|
Thyroid Diseases | 1 | 2016 | 385 | 0.110 |
Why?
|
Fruit | 2 | 2023 | 1165 | 0.110 |
Why?
|
Morals | 1 | 2016 | 288 | 0.110 |
Why?
|
Social Stigma | 2 | 2018 | 788 | 0.110 |
Why?
|
Body Image | 1 | 2018 | 646 | 0.110 |
Why?
|
American Heart Association | 1 | 2018 | 1050 | 0.110 |
Why?
|
Government | 1 | 2014 | 161 | 0.100 |
Why?
|
Hypertriglyceridemia | 1 | 2016 | 293 | 0.100 |
Why?
|
Healthcare Disparities | 3 | 2019 | 3415 | 0.100 |
Why?
|
Apolipoproteins A | 1 | 2012 | 96 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2024 | 4352 | 0.100 |
Why?
|
Calcium Channel Blockers | 3 | 2023 | 687 | 0.100 |
Why?
|
Behavior, Addictive | 1 | 2017 | 428 | 0.100 |
Why?
|
Policy | 1 | 2016 | 513 | 0.100 |
Why?
|
Culture | 1 | 2016 | 622 | 0.100 |
Why?
|
Lipoprotein Lipase | 1 | 2012 | 133 | 0.100 |
Why?
|
Education, Medical | 2 | 2016 | 1742 | 0.100 |
Why?
|
Eating | 2 | 2023 | 1542 | 0.100 |
Why?
|
Insurance Coverage | 1 | 2023 | 1946 | 0.100 |
Why?
|
Membrane Proteins | 2 | 2023 | 7876 | 0.100 |
Why?
|
Growth Disorders | 1 | 2017 | 635 | 0.100 |
Why?
|
Choice Behavior | 1 | 2018 | 848 | 0.100 |
Why?
|
Cell Cycle Proteins | 1 | 2023 | 3445 | 0.100 |
Why?
|
Child Mortality | 1 | 2014 | 204 | 0.100 |
Why?
|
Human Experimentation | 1 | 2012 | 125 | 0.100 |
Why?
|
Siblings | 2 | 2013 | 828 | 0.100 |
Why?
|
Myocardial Revascularization | 4 | 2017 | 795 | 0.100 |
Why?
|
Genetic Variation | 2 | 2017 | 6611 | 0.100 |
Why?
|
Regression Analysis | 2 | 2019 | 6340 | 0.100 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2012 | 313 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1942 | 0.100 |
Why?
|
Weather | 1 | 2013 | 234 | 0.100 |
Why?
|
Health Planning Organizations | 3 | 2015 | 13 | 0.090 |
Why?
|
Clinical Governance | 1 | 2011 | 7 | 0.090 |
Why?
|
Program Development | 3 | 2019 | 1300 | 0.090 |
Why?
|
Publications | 1 | 2013 | 195 | 0.090 |
Why?
|
Interinstitutional Relations | 1 | 2012 | 235 | 0.090 |
Why?
|
Risk | 6 | 2024 | 9613 | 0.090 |
Why?
|
Prescriptions | 1 | 2014 | 388 | 0.090 |
Why?
|
Clinical Protocols | 3 | 2024 | 1443 | 0.090 |
Why?
|
Drug Prescriptions | 1 | 2020 | 1668 | 0.090 |
Why?
|
Transportation | 1 | 2013 | 217 | 0.090 |
Why?
|
Ethics Committees, Research | 1 | 2012 | 196 | 0.090 |
Why?
|
Hospitals | 3 | 2023 | 3886 | 0.090 |
Why?
|
Authorship | 1 | 2014 | 289 | 0.090 |
Why?
|
Insurance, Health | 2 | 2023 | 2517 | 0.090 |
Why?
|
Tertiary Prevention | 1 | 2010 | 8 | 0.090 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20227 | 0.090 |
Why?
|
Syndrome | 1 | 2017 | 3272 | 0.090 |
Why?
|
Research Report | 1 | 2013 | 369 | 0.090 |
Why?
|
Child Welfare | 1 | 2014 | 523 | 0.090 |
Why?
|
Referral and Consultation | 3 | 2020 | 3620 | 0.090 |
Why?
|
Mouth Neoplasms | 1 | 2015 | 597 | 0.090 |
Why?
|
Lipase | 1 | 2012 | 321 | 0.090 |
Why?
|
Indian Ocean Islands | 1 | 2010 | 1 | 0.090 |
Why?
|
Prescription Drugs | 1 | 2018 | 635 | 0.090 |
Why?
|
Diabetic Retinopathy | 1 | 2020 | 1300 | 0.090 |
Why?
|
Health Education | 2 | 2019 | 1059 | 0.090 |
Why?
|
Bone Remodeling | 1 | 2014 | 583 | 0.090 |
Why?
|
Spices | 1 | 2010 | 11 | 0.090 |
Why?
|
Consensus | 1 | 2020 | 3212 | 0.090 |
Why?
|
Risk Management | 1 | 2013 | 558 | 0.090 |
Why?
|
Myocardial Ischemia | 2 | 2018 | 2138 | 0.080 |
Why?
|
Proton Pump Inhibitors | 1 | 2015 | 552 | 0.080 |
Why?
|
Rural Health Services | 1 | 2013 | 394 | 0.080 |
Why?
|
Smoking Cessation | 2 | 2020 | 2085 | 0.080 |
Why?
|
Dairy Products | 1 | 2013 | 490 | 0.080 |
Why?
|
Body Composition | 2 | 2017 | 2462 | 0.080 |
Why?
|
Heart | 1 | 2023 | 4446 | 0.080 |
Why?
|
Pregnancy Complications | 2 | 2024 | 2973 | 0.080 |
Why?
|
Schools | 1 | 2018 | 1498 | 0.080 |
Why?
|
Infant, Newborn | 10 | 2024 | 26422 | 0.080 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2010 | 279 | 0.080 |
Why?
|
Health Communication | 1 | 2012 | 216 | 0.080 |
Why?
|
Infant Mortality | 1 | 2014 | 752 | 0.080 |
Why?
|
Phytosterols | 1 | 2009 | 55 | 0.080 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2010 | 766 | 0.080 |
Why?
|
Precancerous Conditions | 1 | 2015 | 985 | 0.080 |
Why?
|
Sulfonic Acids | 1 | 2009 | 103 | 0.080 |
Why?
|
Angioplasty | 1 | 2011 | 355 | 0.080 |
Why?
|
Interdisciplinary Communication | 1 | 2014 | 937 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 2457 | 0.080 |
Why?
|
Trans Fatty Acids | 1 | 2009 | 155 | 0.070 |
Why?
|
Students | 1 | 2018 | 1744 | 0.070 |
Why?
|
Blood Chemical Analysis | 1 | 2010 | 435 | 0.070 |
Why?
|
Predictive Value of Tests | 4 | 2019 | 15454 | 0.070 |
Why?
|
Cross-Cultural Comparison | 3 | 2019 | 638 | 0.070 |
Why?
|
Genome-Wide Association Study | 5 | 2016 | 12795 | 0.070 |
Why?
|
Ethics, Research | 1 | 2009 | 178 | 0.070 |
Why?
|
Drug Utilization | 1 | 2014 | 1189 | 0.070 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2011 | 475 | 0.070 |
Why?
|
Single-Blind Method | 3 | 2019 | 1587 | 0.070 |
Why?
|
Renal Insufficiency | 4 | 2016 | 812 | 0.070 |
Why?
|
Medical Informatics | 1 | 2015 | 743 | 0.070 |
Why?
|
Cooking | 1 | 2010 | 327 | 0.070 |
Why?
|
Diet, Mediterranean | 1 | 2014 | 748 | 0.070 |
Why?
|
Linear Models | 5 | 2016 | 5884 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2022 | 3447 | 0.070 |
Why?
|
Coronary Vessels | 1 | 2018 | 3124 | 0.070 |
Why?
|
Occupational Diseases | 1 | 2015 | 1457 | 0.070 |
Why?
|
Multivariate Analysis | 4 | 2016 | 12077 | 0.070 |
Why?
|
Confidence Intervals | 2 | 2011 | 2923 | 0.070 |
Why?
|
Lactation | 2 | 2020 | 392 | 0.070 |
Why?
|
Travel | 1 | 2013 | 805 | 0.070 |
Why?
|
Professional Role | 2 | 2020 | 316 | 0.070 |
Why?
|
Access to Information | 1 | 2010 | 317 | 0.070 |
Why?
|
Anticoagulants | 2 | 2020 | 4852 | 0.070 |
Why?
|
Seasons | 1 | 2013 | 1524 | 0.070 |
Why?
|
Thinness | 2 | 2015 | 483 | 0.070 |
Why?
|
Fibrinogen | 1 | 2010 | 891 | 0.070 |
Why?
|
Alcoholism | 1 | 2017 | 1980 | 0.070 |
Why?
|
Uric Acid | 1 | 2013 | 805 | 0.070 |
Why?
|
Tanzania | 1 | 2011 | 1407 | 0.070 |
Why?
|
Health Services Research | 2 | 2019 | 1815 | 0.070 |
Why?
|
Disease Progression | 3 | 2024 | 13671 | 0.070 |
Why?
|
Systole | 2 | 2022 | 937 | 0.070 |
Why?
|
Models, Statistical | 2 | 2020 | 5107 | 0.070 |
Why?
|
International Cooperation | 1 | 2012 | 1436 | 0.060 |
Why?
|
Quantitative Trait Loci | 1 | 2014 | 2131 | 0.060 |
Why?
|
Blood Platelets | 1 | 2016 | 2479 | 0.060 |
Why?
|
Disease | 1 | 2011 | 675 | 0.060 |
Why?
|
Professional-Patient Relations | 1 | 2011 | 724 | 0.060 |
Why?
|
MicroRNAs | 1 | 2022 | 3803 | 0.060 |
Why?
|
Confidentiality | 1 | 2010 | 607 | 0.060 |
Why?
|
Carotid Artery Diseases | 1 | 2012 | 879 | 0.060 |
Why?
|
DNA Primers | 1 | 2010 | 2828 | 0.060 |
Why?
|
Professional Competence | 2 | 2019 | 430 | 0.060 |
Why?
|
Tibet | 2 | 2015 | 10 | 0.060 |
Why?
|
Checklist | 1 | 2012 | 840 | 0.060 |
Why?
|
Age of Onset | 1 | 2012 | 3347 | 0.060 |
Why?
|
Fish Oils | 1 | 2009 | 483 | 0.060 |
Why?
|
Attitude to Health | 1 | 2014 | 2025 | 0.060 |
Why?
|
Genetic Linkage | 1 | 2010 | 2342 | 0.060 |
Why?
|
Data Collection | 1 | 2014 | 3327 | 0.060 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2018 | 1399 | 0.060 |
Why?
|
Combined Modality Therapy | 3 | 2023 | 8542 | 0.060 |
Why?
|
Mendelian Randomization Analysis | 2 | 2021 | 1040 | 0.060 |
Why?
|
Paper | 3 | 2010 | 83 | 0.060 |
Why?
|
Drug Industry | 1 | 2011 | 791 | 0.060 |
Why?
|
Kidney Failure, Chronic | 1 | 2017 | 2496 | 0.060 |
Why?
|
Postoperative Complications | 5 | 2016 | 15832 | 0.060 |
Why?
|
Recurrence | 1 | 2016 | 8509 | 0.060 |
Why?
|
Coronary Angiography | 4 | 2018 | 4541 | 0.060 |
Why?
|
Hyperlipidemias | 1 | 2009 | 772 | 0.060 |
Why?
|
Australia | 2 | 2019 | 1265 | 0.060 |
Why?
|
Organizations | 2 | 2016 | 172 | 0.060 |
Why?
|
Child, Preschool | 9 | 2022 | 42669 | 0.060 |
Why?
|
Intention to Treat Analysis | 2 | 2018 | 416 | 0.060 |
Why?
|
Peptides | 2 | 2013 | 4354 | 0.060 |
Why?
|
Survival Analysis | 3 | 2022 | 10101 | 0.050 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2005 | 394 | 0.050 |
Why?
|
Clinical Laboratory Techniques | 1 | 2009 | 747 | 0.050 |
Why?
|
Kidney | 1 | 2019 | 7064 | 0.050 |
Why?
|
Infant | 7 | 2022 | 36535 | 0.050 |
Why?
|
Genetic Loci | 1 | 2012 | 2629 | 0.050 |
Why?
|
Nerve Tissue Proteins | 2 | 2013 | 4413 | 0.050 |
Why?
|
Self Report | 3 | 2020 | 3773 | 0.050 |
Why?
|
Informed Consent | 1 | 2009 | 1010 | 0.050 |
Why?
|
Software | 2 | 2013 | 4478 | 0.050 |
Why?
|
Ethiopia | 1 | 2024 | 485 | 0.050 |
Why?
|
Patient Selection | 2 | 2012 | 4260 | 0.050 |
Why?
|
Decision Making | 1 | 2016 | 3953 | 0.050 |
Why?
|
DNA | 1 | 2016 | 7214 | 0.050 |
Why?
|
Growth | 1 | 2004 | 366 | 0.050 |
Why?
|
Ambulatory Care | 1 | 2013 | 2783 | 0.050 |
Why?
|
Kenya | 1 | 2024 | 757 | 0.050 |
Why?
|
Adaptation, Psychological | 1 | 2012 | 2663 | 0.050 |
Why?
|
Potassium Iodide | 1 | 2021 | 13 | 0.050 |
Why?
|
Purinergic P2 Receptor Antagonists | 2 | 2012 | 67 | 0.050 |
Why?
|
DNA Methylation | 1 | 2015 | 4428 | 0.050 |
Why?
|
Thiazoles | 1 | 2009 | 1542 | 0.050 |
Why?
|
Inpatients | 1 | 2013 | 2566 | 0.050 |
Why?
|
Pilot Projects | 4 | 2021 | 8741 | 0.050 |
Why?
|
Echocardiography | 1 | 2014 | 5047 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2011 | 6229 | 0.050 |
Why?
|
ROC Curve | 2 | 2024 | 3628 | 0.050 |
Why?
|
Bundle-Branch Block | 1 | 2023 | 278 | 0.050 |
Why?
|
Alleles | 3 | 2017 | 6894 | 0.050 |
Why?
|
United Arab Emirates | 1 | 2020 | 42 | 0.050 |
Why?
|
Antioxidants | 1 | 2009 | 1673 | 0.050 |
Why?
|
Endothelial Cells | 1 | 2013 | 3589 | 0.040 |
Why?
|
Algorithms | 2 | 2018 | 14164 | 0.040 |
Why?
|
Stem Cells | 1 | 2013 | 3537 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7951 | 0.040 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6082 | 0.040 |
Why?
|
Government Regulation | 2 | 2016 | 525 | 0.040 |
Why?
|
Plaque, Atherosclerotic | 1 | 2012 | 1551 | 0.040 |
Why?
|
Spouses | 1 | 2023 | 286 | 0.040 |
Why?
|
Saudi Arabia | 1 | 2020 | 212 | 0.040 |
Why?
|
England | 2 | 2015 | 533 | 0.040 |
Why?
|
Caregivers | 1 | 2012 | 2302 | 0.040 |
Why?
|
Databases, Factual | 1 | 2015 | 8080 | 0.040 |
Why?
|
Lebanon | 1 | 2020 | 245 | 0.040 |
Why?
|
Russia | 1 | 2020 | 386 | 0.040 |
Why?
|
Probability | 1 | 2005 | 2479 | 0.040 |
Why?
|
Work | 1 | 2020 | 195 | 0.040 |
Why?
|
Reoperation | 3 | 2016 | 4329 | 0.040 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2013 | 577 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2020 | 367 | 0.040 |
Why?
|
Aging | 2 | 2018 | 8744 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 4860 | 0.040 |
Why?
|
Diabetic Angiopathies | 1 | 2024 | 806 | 0.040 |
Why?
|
Cardiac Care Facilities | 1 | 2018 | 35 | 0.040 |
Why?
|
Base Sequence | 1 | 2010 | 12421 | 0.040 |
Why?
|
Nurse Administrators | 1 | 2019 | 45 | 0.040 |
Why?
|
Internet | 1 | 2011 | 3110 | 0.040 |
Why?
|
Maternal Health Services | 1 | 2024 | 472 | 0.040 |
Why?
|
Quarantine | 1 | 2021 | 186 | 0.040 |
Why?
|
Absorptiometry, Photon | 2 | 2015 | 1758 | 0.040 |
Why?
|
Databases as Topic | 1 | 2020 | 472 | 0.040 |
Why?
|
Weight Gain | 1 | 2009 | 2359 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2016 | 3436 | 0.040 |
Why?
|
Health Services Needs and Demand | 2 | 2017 | 1406 | 0.040 |
Why?
|
Dietary Fats | 2 | 2020 | 2003 | 0.040 |
Why?
|
Physician Executives | 1 | 2019 | 140 | 0.040 |
Why?
|
Condiments | 1 | 2017 | 7 | 0.040 |
Why?
|
Gene Frequency | 2 | 2017 | 3623 | 0.040 |
Why?
|
Spirometry | 1 | 2021 | 929 | 0.040 |
Why?
|
Anniversaries and Special Events | 1 | 2018 | 97 | 0.040 |
Why?
|
Filtration | 2 | 2009 | 229 | 0.040 |
Why?
|
Multilevel Analysis | 1 | 2017 | 148 | 0.040 |
Why?
|
Temperature | 1 | 2024 | 2234 | 0.030 |
Why?
|
Markov Chains | 1 | 2020 | 979 | 0.030 |
Why?
|
Computer Simulation | 1 | 2010 | 6283 | 0.030 |
Why?
|
Elasticity Imaging Techniques | 1 | 2022 | 398 | 0.030 |
Why?
|
Models, Biological | 2 | 2010 | 9495 | 0.030 |
Why?
|
Communication | 1 | 2011 | 3905 | 0.030 |
Why?
|
Tablets | 1 | 2017 | 149 | 0.030 |
Why?
|
Genotype | 3 | 2017 | 13045 | 0.030 |
Why?
|
Proteins | 1 | 2011 | 6009 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2020 | 6847 | 0.030 |
Why?
|
Diet Records | 1 | 2018 | 426 | 0.030 |
Why?
|
Saliva | 1 | 2021 | 853 | 0.030 |
Why?
|
Education, Graduate | 1 | 2016 | 75 | 0.030 |
Why?
|
Administration, Oral | 2 | 2017 | 4030 | 0.030 |
Why?
|
Forced Expiratory Volume | 1 | 2021 | 1831 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2021 | 812 | 0.030 |
Why?
|
Ireland | 1 | 2015 | 170 | 0.030 |
Why?
|
Hand Strength | 1 | 2018 | 466 | 0.030 |
Why?
|
Snoring | 1 | 2017 | 211 | 0.030 |
Why?
|
Vitamins | 2 | 2014 | 1638 | 0.030 |
Why?
|
Standard of Care | 1 | 2020 | 568 | 0.030 |
Why?
|
Finland | 1 | 2017 | 609 | 0.030 |
Why?
|
Body Height | 2 | 2014 | 1565 | 0.030 |
Why?
|
Hospital Mortality | 3 | 2015 | 5349 | 0.030 |
Why?
|
Hashimoto Disease | 1 | 2016 | 108 | 0.030 |
Why?
|
Sanitation | 1 | 2015 | 83 | 0.030 |
Why?
|
Death, Sudden, Cardiac | 1 | 2023 | 1567 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2020 | 905 | 0.030 |
Why?
|
New Zealand | 1 | 2015 | 360 | 0.030 |
Why?
|
Middle East | 1 | 2015 | 233 | 0.030 |
Why?
|
Feedback | 1 | 2019 | 799 | 0.030 |
Why?
|
Sympathectomy | 1 | 2015 | 72 | 0.030 |
Why?
|
Awareness | 1 | 2019 | 654 | 0.030 |
Why?
|
Databases, Bibliographic | 1 | 2015 | 128 | 0.030 |
Why?
|
Early Detection of Cancer | 2 | 2022 | 3239 | 0.030 |
Why?
|
Hyperthyroidism | 1 | 2016 | 292 | 0.030 |
Why?
|
Genomics | 1 | 2010 | 5926 | 0.030 |
Why?
|
Monitoring, Ambulatory | 1 | 2018 | 358 | 0.030 |
Why?
|
Nutritive Value | 1 | 2017 | 351 | 0.030 |
Why?
|
Dental Alloys | 1 | 2013 | 29 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2021 | 1126 | 0.030 |
Why?
|
Social Problems | 1 | 2014 | 108 | 0.030 |
Why?
|
Health Planning Guidelines | 1 | 2014 | 153 | 0.030 |
Why?
|
Milk, Human | 1 | 2018 | 490 | 0.030 |
Why?
|
Learning | 1 | 2023 | 1759 | 0.030 |
Why?
|
Platelet Aggregation | 1 | 2016 | 769 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2015 | 297 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2013 | 64 | 0.030 |
Why?
|
Sample Size | 1 | 2016 | 846 | 0.030 |
Why?
|
Efficiency | 1 | 2016 | 479 | 0.030 |
Why?
|
Nutritional Requirements | 1 | 2014 | 279 | 0.030 |
Why?
|
Occupations | 1 | 2015 | 516 | 0.030 |
Why?
|
Genetic Association Studies | 2 | 2012 | 2744 | 0.030 |
Why?
|
Nephrology | 1 | 2016 | 270 | 0.030 |
Why?
|
Medically Underserved Area | 1 | 2015 | 268 | 0.030 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2013 | 152 | 0.030 |
Why?
|
Georgia | 1 | 2012 | 186 | 0.030 |
Why?
|
General Practitioners | 1 | 2013 | 103 | 0.020 |
Why?
|
Muscle Development | 1 | 2014 | 258 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2014 | 426 | 0.020 |
Why?
|
Sports | 1 | 2018 | 703 | 0.020 |
Why?
|
Focus Groups | 1 | 2018 | 1460 | 0.020 |
Why?
|
Meat | 1 | 2015 | 588 | 0.020 |
Why?
|
Bicycling | 1 | 2013 | 177 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2015 | 948 | 0.020 |
Why?
|
Survivors | 1 | 2022 | 2381 | 0.020 |
Why?
|
Hypothyroidism | 1 | 2016 | 667 | 0.020 |
Why?
|
Diastole | 1 | 2014 | 785 | 0.020 |
Why?
|
Time | 1 | 2013 | 552 | 0.020 |
Why?
|
Glucose | 1 | 2023 | 4352 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2013 | 520 | 0.020 |
Why?
|
Long-Term Care | 1 | 2015 | 631 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2015 | 1062 | 0.020 |
Why?
|
Thrombolytic Therapy | 1 | 2020 | 2055 | 0.020 |
Why?
|
Albuminuria | 1 | 2015 | 658 | 0.020 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 428 | 0.020 |
Why?
|
Clinical Competence | 2 | 2019 | 4858 | 0.020 |
Why?
|
Netherlands | 1 | 2015 | 2277 | 0.020 |
Why?
|
Bone Development | 1 | 2014 | 473 | 0.020 |
Why?
|
Counseling | 1 | 2018 | 1554 | 0.020 |
Why?
|
Western World | 1 | 2010 | 27 | 0.020 |
Why?
|
Heparin | 1 | 2018 | 1636 | 0.020 |
Why?
|
Diuretics | 1 | 2013 | 614 | 0.020 |
Why?
|
HIV Infections | 1 | 2017 | 17569 | 0.020 |
Why?
|
Risk Adjustment | 1 | 2014 | 599 | 0.020 |
Why?
|
North America | 1 | 2014 | 1289 | 0.020 |
Why?
|
Advisory Committees | 1 | 2014 | 797 | 0.020 |
Why?
|
Acetates | 1 | 2011 | 317 | 0.020 |
Why?
|
Adolescent Behavior | 1 | 2018 | 1186 | 0.020 |
Why?
|
Creatinine | 1 | 2015 | 1918 | 0.020 |
Why?
|
Frail Elderly | 1 | 2015 | 781 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2784 | 0.020 |
Why?
|
Philippines | 1 | 2009 | 95 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2020 | 2907 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2011 | 716 | 0.020 |
Why?
|
Drug Resistance | 1 | 2015 | 1599 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 2937 | 0.020 |
Why?
|
Motivation | 1 | 2018 | 2020 | 0.020 |
Why?
|
Spectrophotometry | 1 | 2009 | 292 | 0.020 |
Why?
|
Capsules | 1 | 2009 | 193 | 0.020 |
Why?
|
Guatemala | 1 | 2009 | 161 | 0.020 |
Why?
|
Fatty Acids, Monounsaturated | 1 | 2009 | 190 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2017 | 1751 | 0.020 |
Why?
|
Receptors, CXCR4 | 1 | 2013 | 729 | 0.020 |
Why?
|
Actigraphy | 1 | 2012 | 527 | 0.020 |
Why?
|
Benzothiazoles | 1 | 2009 | 248 | 0.020 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2017 | 1107 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4120 | 0.020 |
Why?
|
Cell Cycle | 1 | 2015 | 2932 | 0.020 |
Why?
|
Polysaccharides | 1 | 2014 | 1024 | 0.020 |
Why?
|
Family Practice | 1 | 2010 | 509 | 0.020 |
Why?
|
Osteoporosis | 1 | 2017 | 1605 | 0.020 |
Why?
|
Tyrosine | 1 | 2011 | 1427 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 714 | 0.020 |
Why?
|
Apolipoproteins | 1 | 2009 | 328 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 1143 | 0.020 |
Why?
|
DNA Repair | 1 | 2015 | 2050 | 0.020 |
Why?
|
Epidemics | 1 | 2012 | 517 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2019 | 3488 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2862 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1078 | 0.020 |
Why?
|
Lumbar Vertebrae | 1 | 2015 | 1885 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2013 | 1281 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2012 | 1309 | 0.020 |
Why?
|
Abdominal Fat | 1 | 2007 | 220 | 0.020 |
Why?
|
Occupational Exposure | 1 | 2015 | 1807 | 0.020 |
Why?
|
Curriculum | 1 | 2018 | 3782 | 0.010 |
Why?
|
Brazil | 1 | 2009 | 1250 | 0.010 |
Why?
|
Specimen Handling | 1 | 2009 | 708 | 0.010 |
Why?
|
Peer Review, Research | 1 | 2007 | 344 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2015 | 5797 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2013 | 2429 | 0.010 |
Why?
|
Thyroid Neoplasms | 1 | 2016 | 2360 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2016 | 3109 | 0.010 |
Why?
|
Fibrinolytic Agents | 1 | 2012 | 2080 | 0.010 |
Why?
|
Cold Temperature | 1 | 2006 | 791 | 0.010 |
Why?
|
Cardiomyopathies | 1 | 2014 | 2056 | 0.010 |
Why?
|
Catheter Ablation | 1 | 2015 | 2780 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2013 | 4427 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2011 | 2650 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3603 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 20760 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2011 | 2100 | 0.010 |
Why?
|
Heart Rate | 1 | 2012 | 4214 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2007 | 1793 | 0.010 |
Why?
|
Adipocytes | 1 | 2007 | 1197 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2012 | 3329 | 0.010 |
Why?
|
Apoptosis | 1 | 2015 | 9523 | 0.010 |
Why?
|
Drug Costs | 1 | 2007 | 1195 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2007 | 1162 | 0.010 |
Why?
|
Reference Values | 1 | 2005 | 4938 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16726 | 0.010 |
Why?
|
Animals | 2 | 2022 | 169246 | 0.010 |
Why?
|
Transcription Factors | 1 | 2013 | 12168 | 0.010 |
Why?
|